NEW YORK -- A team of Columbia scientists have discovered two genes that, when simultaneously activated, are responsible for the most aggressive forms of human brain cancerThis finding was made possible by the assembly of the first comprehensive network of molecular interactions that determine the

read more>>

Children and adolescents who survive cancer have a significantly higher risk of developing heart disease as young adults, according to the largest study on this issue published on bmj.com todayThe findings show that young adult survivors of childhood cancer are at risk for a variety of cardiovascu

read more>>

TUSTIN, Calif. -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancerCotara is a targeted monoclonal anti

read more>>

Dr. Howard Riina threaded a slender tube through a maze of arteries in Dennis Sugrue’s brain, watching X-ray images on a monitor to track his progress.At the site where a previous operation had removed a malignant tumor, he infused a drug called mannitol and unleashed a flood of the cancer

read more>>

Heidelberg -- Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, today announced that the European Medicines Agency adopted a positive opinion on orphan medicinal product designation for the company’s lead candidate APG101 for the treatm

read more>>

Researchers from University Hospitals Case Medical Center report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a novel type of imaging called MR spectroscopy coupled with high dose radiation in the form of Gamma Knife radiosurgery.Patients' survival rates increased by almost four months (3.7 months) compared with…

read more>>

MALVERN, Pa., -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New…

read more>>

Seattle — Imagine this: You’re 31 and in the prime of your life. You have a family with two little girls, and the job you always dreamed of. One day, out of the blue, you have a seizure. The doctor sends you in for an MRI. It turns out that seizure was a symptom of something much more serious—you have brain cancer. And now, you’re in the fight of your life.

read more>>

PHOENIX, Ariz. – SAIC-Frederick Inc., under its prime contract with the National Cancer Institute, has named the Translational Genomics Research Institute (TGen) as one of five national centers selected to conduct cancer experiments using advanced computer simulations.

read more>>

In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. The study is scheduled for the Sept. 9 issue of ACS' Nano Letters, a monthly journal.

read more>>